NCT03916094 2022-05-05
Evaluate Safety, Tolerability and Pharmacokinetics of HLX22 in Patients With Advanced Solid Tumors Overexpressing HER2
Shanghai Henlius Biotech
Phase 1 Completed
Clinical Trials
4 trialsNCT00022529 2013-01-25
BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00042809 2013-01-24
Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00084513 2010-02-12
Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer
Fox Chase Cancer Center
Phase 1 Completed